US EditionOzempic and Wegovy: Weight Rebound Risks After Stopping Treatment
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
[Article already published on August 24, 2025] For several years, rapid weight loss has become a widely valued goal, well beyond medical issues. In this context, some treatments initially developed for diabetes have experienced a staggering rise, until they become products of trend. Among them, semaglutide has been imposed as a miracle solution for many patients. But behind this success, an unexpected alert is beginning to emerge, affecting a mu…
Ozempic and Wegovy: Weight Rebound Risks After Stopping Treatment
In the burgeoning field of obesity treatment, glucagon-like peptide-1 (GLP-1) receptor agonists like Ozempic and Wegovy have emerged as game-changers, helping millions shed significant pounds by mimicking hormones that regulate appetite and blood sugar. Yet, a growing body of evidence suggests that discontinuing these medications can lead to a harsh backlash: intense hunger pangs, rapid weight regain, and in some cases, even greater weight gain …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
